<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Arch Med Sci</journal-id><journal-id journal-id-type="publisher-id">AMS</journal-id><journal-title-group><journal-title>Archives of Medical Science : AMS</journal-title></journal-title-group><issn pub-type="ppub">1734-1922</issn><issn pub-type="epub">1896-9151</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25097576</article-id><article-id pub-id-type="pmc">4107254</article-id><article-id pub-id-type="publisher-id">23014</article-id><article-id pub-id-type="doi">10.5114/aoms.2014.43742</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>A survey to establish current methods of venous thromboembolism prophylaxis in stroke patients practiced by Polish neurologists</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Bembenek</surname><given-names>Jan Paweł</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Dennis</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Czlonkowska</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="aff" rid="AF0003">3</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>2<sup>nd</sup> Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland</aff><aff id="AF0002"><label>2</label>Division of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland</aff><aff id="AF0003"><label>3</label>Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Jan Paweł Bembenek MD, PhD, 2<sup>nd</sup> Department of Neurology, Institute of Psychiatry and Neurology, 9 Sobieskiego St, 02-957 Warsaw, Poland. Phone: +48 22 458 28 72, Fax: +48 22 842 40 23. E-mail: <email xlink:href="jbembenek@o2.pl">jbembenek@o2.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>6</month><year>2014</year></pub-date><pub-date pub-type="ppub"><day>29</day><month>6</month><year>2014</year></pub-date><volume>10</volume><issue>3</issue><fpage>470</fpage><lpage>476</lpage><history><date date-type="received"><day>04</day><month>12</month><year>2012</year></date><date date-type="rev-recd"><day>17</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2014 Termedia &amp; Banach</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3534" xml_f="3546" txt_i="11" txt_f="23">Introduction</offsets></title><p><offsets xml_i="3557" xml_f="3928" txt_i="24" txt_f="395">Venous thromboembolism (VTE) is associated with considerable morbidity and mortality in stroke patients. The purpose of our survey was to establish the current methods of VTE prophylaxis practiced by Polish neurologists. We also aimed to determine whether there is enough variation in practice to justify the development of an evidence-based guideline for VTE prevention.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3959" xml_f="3979" txt_i="397" txt_f="417">Material and methods</offsets></title><p><offsets xml_i="3990" xml_f="4272" txt_i="418" txt_f="700">Postal self-administered questionnaires about VTE prophylactic methods practiced by Polish neurologists were sent to 218 neurological wards where stroke is treated. If no response was received, the questionnaire was faxed and finally we attempted to obtain information by telephone.</offsets></p></sec><sec id="st3"><title><offsets xml_i="4303" xml_f="4310" txt_i="702" txt_f="709">Results</offsets></title><p><offsets xml_i="4321" xml_f="4799" txt_i="710" txt_f="1188">One hundred and seventy-six (80.7%) stroke centers of 218 responded. The majority (137/176; 77.8%) of centers had a stroke unit. The median admission rate of surveyed wards was estimated to be 320 patients/year (range from 20 to 1000 patients/year). The most common method of VTE prophylaxis reported was low molecular weight heparin (LMWH) (98.9%), and the least common was intermittent pneumatic compression (IPC) (6.8%). Centers admitting ≥ 200 patients/year (70.7% vs. 45%; </offsets><italic><offsets xml_i="4807" xml_f="4808" txt_i="1188" txt_f="1189">p</offsets></italic><offsets xml_i="4817" xml_f="4868" txt_i="1189" txt_f="1240"> = 0.039), and those with stroke units (95 vs. 20; </offsets><italic><offsets xml_i="4876" xml_f="4877" txt_i="1240" txt_f="1241">p</offsets></italic><offsets xml_i="4886" xml_f="5074" txt_i="1241" txt_f="1429"> = 0.031) were more willing to join a randomized trial evaluating any of the methods. All the centers participating in the survey reported a need for a detailed VTE prophylaxis guidelines.</offsets></p></sec><sec id="st4"><title><offsets xml_i="5105" xml_f="5116" txt_i="1431" txt_f="1442">Conclusions</offsets></title><p><offsets xml_i="5127" xml_f="5376" txt_i="1443" txt_f="1692">The LMWH is the predominant VTE prophylaxis strategy for stroke patients practiced by Polish neurologists. Due to the variation of methods used in VTE prophylaxis it might be reasonable to further specify this section of stroke treatment guidelines.</offsets></p></sec></abstract><kwd-group><kwd>stroke</kwd><kwd>deep venous thrombosis</kwd><kwd>venous thromboembolism</kwd><kwd>prophylaxis</kwd><kwd>pulmonary embolism</kwd><kwd>survey</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title><offsets xml_i="5640" xml_f="5652" txt_i="1701" txt_f="1713">Introduction</offsets></title><p><offsets xml_i="5663" xml_f="5831" txt_i="1714" txt_f="1882">Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and its sequela, pulmonary embolism (PE), is an important cause of illness and death after stroke [</offsets><xref rid="CIT0001" ref-type="bibr"><offsets xml_i="5867" xml_f="5868" txt_i="1882" txt_f="1883">1</offsets></xref><offsets xml_i="5875" xml_f="5993" txt_i="1883" txt_f="2001">]. At greatest risk are patients who are immobile, with significant weakness of the limbs and a prior history of DVT [</offsets><xref rid="CIT0002" ref-type="bibr"><offsets xml_i="6029" xml_f="6030" txt_i="2001" txt_f="2002">2</offsets></xref><offsets xml_i="6037" xml_f="6194" txt_i="2002" txt_f="2159">]. Depending on the methodology of the studies, the frequency of DVT is up to 80% of patients with ischemic stroke who did not receive prophylactic therapy [</offsets><xref rid="CIT0003" ref-type="bibr"><offsets xml_i="6230" xml_f="6231" txt_i="2159" txt_f="2160">3</offsets></xref><offsets xml_i="6238" xml_f="6326" txt_i="2160" txt_f="2248">]. The frequency of above-knee DVT using Doppler ultrasound technique was lower (∼10%) [</offsets><xref rid="CIT0004" ref-type="bibr"><offsets xml_i="6362" xml_f="6363" txt_i="2248" txt_f="2249">4</offsets></xref><offsets xml_i="6370" xml_f="6371" txt_i="2249" txt_f="2250">–</offsets><xref rid="CIT0006" ref-type="bibr"><offsets xml_i="6407" xml_f="6408" txt_i="2250" txt_f="2251">6</offsets></xref><offsets xml_i="6415" xml_f="6618" txt_i="2251" txt_f="2454">]. Additionally, the types of patients included and the duration and timing of follow-up influenced the estimates. Approximately 5% of early deaths following stroke are attributed to pulmonary embolism [</offsets><xref rid="CIT0001" ref-type="bibr"><offsets xml_i="6654" xml_f="6655" txt_i="2454" txt_f="2455">1</offsets></xref><offsets xml_i="6662" xml_f="6664" txt_i="2455" txt_f="2457">].</offsets></p><p><offsets xml_i="6671" xml_f="6970" txt_i="2458" txt_f="2757">There are pharmacological (unfractionated heparin – UFH, low-molecular-weight heparins – LMWH, oral anticoagulants, new oral anticoagulants, dextrans) and physical methods (graduated compression stockings (GCS), intermittent pneumatic compression devices (IPC)) which aim to reduce the risk of VTE [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="7006" xml_f="7007" txt_i="2757" txt_f="2758">7</offsets></xref><offsets xml_i="7014" xml_f="7016" txt_i="2758" txt_f="2760">, </offsets><xref rid="CIT0008" ref-type="bibr"><offsets xml_i="7052" xml_f="7053" txt_i="2760" txt_f="2761">8</offsets></xref><offsets xml_i="7060" xml_f="7299" txt_i="2761" txt_f="3000">]. The strength of evidence for each varies. There is no “gold standard” method for VTE prevention that is recommended in all post-stroke patients. Inevitably, where reliable evidence is not available, variation in recommendations exists [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="7335" xml_f="7336" txt_i="3000" txt_f="3001">7</offsets></xref><offsets xml_i="7343" xml_f="7345" txt_i="3001" txt_f="3003">, </offsets><xref rid="CIT0009" ref-type="bibr"><offsets xml_i="7381" xml_f="7382" txt_i="3003" txt_f="3004">9</offsets></xref><offsets xml_i="7389" xml_f="7390" txt_i="3004" txt_f="3005">–</offsets><xref rid="CIT0011" ref-type="bibr"><offsets xml_i="7426" xml_f="7428" txt_i="3005" txt_f="3007">11</offsets></xref><offsets xml_i="7435" xml_f="7437" txt_i="3007" txt_f="3009">].</offsets></p><p><offsets xml_i="7444" xml_f="7643" txt_i="3010" txt_f="3209">There are no reliable data regarding the variation in use of VTE prophylactic methods in Poland and the multiplicity of the available recommendations and guidelines can contribute to such diversity [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="7679" xml_f="7680" txt_i="3209" txt_f="3210">7</offsets></xref><offsets xml_i="7687" xml_f="7689" txt_i="3210" txt_f="3212">, </offsets><xref rid="CIT0009" ref-type="bibr"><offsets xml_i="7725" xml_f="7726" txt_i="3212" txt_f="3213">9</offsets></xref><offsets xml_i="7733" xml_f="7734" txt_i="3213" txt_f="3214">–</offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="7770" xml_f="7772" txt_i="3214" txt_f="3216">13</offsets></xref><offsets xml_i="7779" xml_f="8056" txt_i="3216" txt_f="3493">]. However, it is important to find out whether such variation exists amongst Polish stroke units and neurological wards. In contrast to other countries such as England or Scotland, in Poland stroke is generally treated in stroke units, which are a part of neurological wards [</offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="8092" xml_f="8094" txt_i="3493" txt_f="3495">13</offsets></xref><offsets xml_i="8101" xml_f="8103" txt_i="3495" txt_f="3497">].</offsets></p><p><offsets xml_i="8110" xml_f="8322" txt_i="3498" txt_f="3710">National surveys may bring interesting and valuable information about variation of clinical practice among the centers in the country, especially when there are discrepancies in data derived from the literature [</offsets><xref rid="CIT0014" ref-type="bibr"><offsets xml_i="8358" xml_f="8360" txt_i="3710" txt_f="3712">14</offsets></xref><offsets xml_i="8367" xml_f="8369" txt_i="3712" txt_f="3714">].</offsets></p><p><offsets xml_i="8376" xml_f="8414" txt_i="3715" txt_f="3753">The aim of the study was to establish:</offsets><list list-type="bullet"><list-item><p><offsets xml_i="8453" xml_f="8548" txt_i="3753" txt_f="3848">whether Polish neurologists working in neurological wards and stroke units use VTE prophylaxis;</offsets></p></list-item><list-item><p><offsets xml_i="8578" xml_f="8621" txt_i="3849" txt_f="3892">what methods are used in each ward or unit;</offsets></p></list-item><list-item><p><offsets xml_i="8651" xml_f="8819" txt_i="3893" txt_f="4061">whether there is much variation in practice and whether it is sufficient to justify the development of an evidence-based guideline specifically for Polish neurologists;</offsets></p></list-item><list-item><p><offsets xml_i="8849" xml_f="9093" txt_i="4062" txt_f="4306">whether there is enough uncertainty regarding which method of VTE prophylaxis should be chosen in stroke that will encourage Polish neurologists to participate in randomized trials comparing different methods of prophylaxis practiced in Poland.</offsets></p></list-item></list><offsets xml_i="9116" xml_f="9117" txt_i="4307" txt_f="4308">
</offsets></p></sec><sec sec-type="materials|methods" id="S0002"><title><offsets xml_i="9179" xml_f="9199" txt_i="4310" txt_f="4330">Material and methods</offsets></title><p><offsets xml_i="9210" xml_f="9231" txt_i="4331" txt_f="4352">A questionnaire (see </offsets><xref ref-type="sec" rid="S0005"><offsets xml_i="9264" xml_f="9276" txt_i="4352" txt_f="4364">Supplement 1</offsets></xref><offsets xml_i="9283" xml_f="10587" txt_i="4364" txt_f="5668">) was sent to all neurological wards listed in the Polish Ministry of Health as treating stroke. The questionnaire comprised five questions. The answers were yes or no, and the only response that required a definite number was an estimate of the number of stroke patients admitted per year. Heads of the departments/wards were asked: whether they have a stroke unit in their hospital; approximately how many stroke patients are admitted to their center per year; what method(s) they use in their departments (multiple choice option: UFH, LMWH, oral anticoagulants, new oral anticoagulants, dextrans, hydration, early mobilization, GCS – full length or below knee, IPC); and also whether they use those methods routinely or in selected patients (when hemorrhagic stroke was excluded; only those at substantial risk of VTE development; individual decision for each patient). We also asked whether respondents would be interested in joining a randomized trial evaluating any of the prophylactic methods (interested in joining a trial evaluating any method: yes or not; and response options: UFH, LMWH, oral anticoagulants, dextrans, GCS, IPC). Additionally, respondents were asked if it would be useful to publish detailed Polish guidelines of VTE prevention in stroke patients (response option: yes or no).</offsets></p><p><offsets xml_i="10594" xml_f="10768" txt_i="5669" txt_f="5843">The questionnaire was first sent by e-mail. If the centers did not respond to the survey, the questionnaire was sent by fax. The last attempt was to obtain data by telephone.</offsets></p><p><offsets xml_i="10775" xml_f="10989" txt_i="5844" txt_f="6058">The survey was conducted between January and May 2012. Participation was voluntary and all responses were confidential. We received only one response from each center (usually provided by a Head of the Department).</offsets></p><p><offsets xml_i="10996" xml_f="11219" txt_i="6059" txt_f="6279">As well as reporting the overall results we also compared the responses of the centers with a stroke unit with those without one and centers admitting ≥ 200 patients/per year with those admitting &lt; 200 patients/per year.</offsets></p><sec id="S20003"><title><offsets xml_i="11247" xml_f="11267" txt_i="6280" txt_f="6300">Statistical analysis</offsets></title><p><offsets xml_i="11278" xml_f="11399" txt_i="6301" txt_f="6422">The mean, range and percentage were noted for descriptive summary statistics. Nominal variables were compared using the χ</offsets><sup><offsets xml_i="11404" xml_f="11405" txt_i="6422" txt_f="6423">2</offsets></sup><offsets xml_i="11411" xml_f="11483" txt_i="6423" txt_f="6495"> test or two-sided exact Fisher's test if the expected value was ≤ 5. A </offsets><italic><offsets xml_i="11491" xml_f="11492" txt_i="6495" txt_f="6496">p</offsets></italic><offsets xml_i="11501" xml_f="11634" txt_i="6496" txt_f="6626"> value &lt; 0.05 was considered statistically significant. Calculations were carried out in Statistica 10.0 PL (StatSoft, Inc. 2011).</offsets></p></sec></sec><sec sec-type="results" id="S0003"><title><offsets xml_i="11692" xml_f="11699" txt_i="6629" txt_f="6636">Results</offsets></title><p><offsets xml_i="11710" xml_f="12010" txt_i="6637" txt_f="6937">Of 218 neurological wards and/or stroke units in Poland, 176 (80.7%) responded to our survey. The majority of the centers participating in the survey had stroke units (137/176, 77.8%). The median number of estimated stroke hospitalizations was 320 patients/year (range from 20 to 1000 patients/year).</offsets></p><p><offsets xml_i="12017" xml_f="12085" txt_i="6938" txt_f="7006">All centers reported the use of several methods of VTE prophylaxis (</offsets><xref ref-type="table" rid="T0001"><offsets xml_i="12120" xml_f="12127" txt_i="7006" txt_f="7013">Table I</offsets></xref><offsets xml_i="12134" xml_f="12361" txt_i="7013" txt_f="7240">). Low molecular weight heparin was the predominant VTE prophylactic strategy (174/176, 98.9%). The least frequently used were IPC devices (12/176, 6.8%). A detailed presentation of frequency of the methods used is provided in </offsets><xref ref-type="fig" rid="F0001"><offsets xml_i="12394" xml_f="12402" txt_i="7240" txt_f="7248">Figure 1</offsets></xref><offsets xml_i="12409" xml_f="12411" txt_i="7248" txt_f="7250">.
</offsets></p><fig id="F0001" position="float"><label><offsets xml_i="12455" xml_f="12463" txt_i="7251" txt_f="7259">Figure 1</offsets></label><caption><p><offsets xml_i="12483" xml_f="12580" txt_i="7259" txt_f="7356">Methods used for VTE prevention in stroke patients in Polish centers that responded to the survey</offsets></p></caption><graphic xlink:href="AMS-10-23014-g001"></graphic></fig><table-wrap id="T0001" position="float"><label><offsets xml_i="12697" xml_f="12704" txt_i="7357" txt_f="7364">Table I</offsets></label><caption><p><offsets xml_i="12724" xml_f="12799" txt_i="7364" txt_f="7439">The simultaneous use of different VTE prophylaxis methods by Polish centers</offsets></p></caption><table frame="border" rules="rows" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="12913" xml_f="12922" txt_i="7440" txt_f="7449">Parameter</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="12970" xml_f="12975" txt_i="7449" txt_f="7454">UHF (</offsets><italic><offsets xml_i="12983" xml_f="12984" txt_i="7454" txt_f="7455">n</offsets></italic><offsets xml_i="12993" xml_f="12999" txt_i="7455" txt_f="7461"> = 31)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13047" xml_f="13053" txt_i="7461" txt_f="7467">LMWH (</offsets><italic><offsets xml_i="13061" xml_f="13062" txt_i="7467" txt_f="7468">n</offsets></italic><offsets xml_i="13071" xml_f="13078" txt_i="7468" txt_f="7475"> = 174)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13126" xml_f="13147" txt_i="7475" txt_f="7496">Oral anticoagulants (</offsets><italic><offsets xml_i="13155" xml_f="13156" txt_i="7496" txt_f="7497">n</offsets></italic><offsets xml_i="13165" xml_f="13171" txt_i="7497" txt_f="7503"> = 82)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13219" xml_f="13244" txt_i="7503" txt_f="7528">New oral anticoagulants (</offsets><italic><offsets xml_i="13252" xml_f="13253" txt_i="7528" txt_f="7529">n</offsets></italic><offsets xml_i="13262" xml_f="13268" txt_i="7529" txt_f="7535"> = 19)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13316" xml_f="13326" txt_i="7535" txt_f="7545">Dextrans (</offsets><italic><offsets xml_i="13334" xml_f="13335" txt_i="7545" txt_f="7546">n</offsets></italic><offsets xml_i="13344" xml_f="13350" txt_i="7546" txt_f="7552"> = 16)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13398" xml_f="13409" txt_i="7552" txt_f="7563">Hydration (</offsets><italic><offsets xml_i="13417" xml_f="13418" txt_i="7563" txt_f="7564">n</offsets></italic><offsets xml_i="13427" xml_f="13434" txt_i="7564" txt_f="7571"> = 137)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13482" xml_f="13502" txt_i="7571" txt_f="7591">Early mobilization (</offsets><italic><offsets xml_i="13510" xml_f="13511" txt_i="7591" txt_f="7592">n</offsets></italic><offsets xml_i="13520" xml_f="13527" txt_i="7592" txt_f="7599"> = 163)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13575" xml_f="13592" txt_i="7599" txt_f="7616">GCS full length (</offsets><italic><offsets xml_i="13600" xml_f="13601" txt_i="7616" txt_f="7617">n</offsets></italic><offsets xml_i="13610" xml_f="13616" txt_i="7617" txt_f="7623"> = 22)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13664" xml_f="13680" txt_i="7623" txt_f="7639">GCS below knee (</offsets><italic><offsets xml_i="13688" xml_f="13689" txt_i="7639" txt_f="7640">n</offsets></italic><offsets xml_i="13698" xml_f="13704" txt_i="7640" txt_f="7646"> = 14)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="13752" xml_f="13757" txt_i="7646" txt_f="7651">IPC (</offsets><italic><offsets xml_i="13765" xml_f="13766" txt_i="7651" txt_f="7652">n</offsets></italic><offsets xml_i="13775" xml_f="13781" txt_i="7652" txt_f="7658"> = 12)</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13851" xml_f="13854" txt_i="7658" txt_f="7661">UHF</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="13950" xml_f="13960" txt_i="7663" txt_f="7673">29 (16.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14008" xml_f="14018" txt_i="7674" txt_f="7684">22 (26.8%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14066" xml_f="14075" txt_i="7685" txt_f="7694">6 (31.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14123" xml_f="14130" txt_i="7695" txt_f="7702">4 (25%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14178" xml_f="14188" txt_i="7703" txt_f="7713">29 (21.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14236" xml_f="14246" txt_i="7714" txt_f="7724">27 (16.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14294" xml_f="14302" txt_i="7725" txt_f="7733">1 (4.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14350" xml_f="14358" txt_i="7734" txt_f="7742">1 (7.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14406" xml_f="14416" txt_i="7743" txt_f="7753">30 (18.3%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14471" xml_f="14475" txt_i="7754" txt_f="7758">LMWH</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14523" xml_f="14533" txt_i="7759" txt_f="7769">29 (93.6%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14629" xml_f="14639" txt_i="7771" txt_f="7781">81 (98.8%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14687" xml_f="14697" txt_i="7782" txt_f="7792">18 (94.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14745" xml_f="14755" txt_i="7793" txt_f="7803">15 (93.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14803" xml_f="14814" txt_i="7804" txt_f="7815">136 (99.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14862" xml_f="14872" txt_i="7816" txt_f="7826">163 (100%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14920" xml_f="14929" txt_i="7827" txt_f="7836">22 (100%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="14977" xml_f="14986" txt_i="7837" txt_f="7846">14 (100%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15034" xml_f="15043" txt_i="7847" txt_f="7856">12 (100%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15098" xml_f="15117" txt_i="7857" txt_f="7876">Oral anticoagulants</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15165" xml_f="15175" txt_i="7877" txt_f="7887">22 (71.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15223" xml_f="15233" txt_i="7888" txt_f="7898">81 (46.6%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15329" xml_f="15339" txt_i="7900" txt_f="7910">15 (79.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15387" xml_f="15397" txt_i="7911" txt_f="7921">10 (62.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15445" xml_f="15455" txt_i="7922" txt_f="7932">69 (50.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15503" xml_f="15513" txt_i="7933" txt_f="7943">78 (47.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15561" xml_f="15569" txt_i="7944" txt_f="7952">11 (50%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15617" xml_f="15624" txt_i="7953" txt_f="7960">7 (50%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15672" xml_f="15681" txt_i="7961" txt_f="7970">5 (41.7%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15736" xml_f="15759" txt_i="7971" txt_f="7994">New oral anticoagulants</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15807" xml_f="15816" txt_i="7995" txt_f="8004">6 (19.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15864" xml_f="15874" txt_i="8005" txt_f="8015">18 (10.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="15922" xml_f="15932" txt_i="8016" txt_f="8026">15 (18.3%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16028" xml_f="16037" txt_i="8028" txt_f="8037">5 (31.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16085" xml_f="16095" txt_i="8038" txt_f="8048">17 (12.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16143" xml_f="16153" txt_i="8049" txt_f="8059">17 (10.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16201" xml_f="16209" txt_i="8060" txt_f="8068">2 (9.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16257" xml_f="16266" txt_i="8069" txt_f="8078">4 (28.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16314" xml_f="16323" txt_i="8079" txt_f="8088">2 (16.7%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16378" xml_f="16386" txt_i="8089" txt_f="8097">Dextrans</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16434" xml_f="16443" txt_i="8098" txt_f="8107">4 (12.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16491" xml_f="16500" txt_i="8108" txt_f="8117">15 (8.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16548" xml_f="16558" txt_i="8118" txt_f="8128">10 (12.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16606" xml_f="16615" txt_i="8129" txt_f="8138">5 (26.3%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16711" xml_f="16720" txt_i="8140" txt_f="8149">13 (9.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16768" xml_f="16777" txt_i="8150" txt_f="8159">12 (7.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16825" xml_f="16833" txt_i="8160" txt_f="8168">1 (4.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16881" xml_f="16890" txt_i="8169" txt_f="8178">2 (14.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16938" xml_f="16944" txt_i="8179" txt_f="8185">0 (0%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16999" xml_f="17008" txt_i="8186" txt_f="8195">Hydration</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17056" xml_f="17066" txt_i="8196" txt_f="8206">29 (93.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17114" xml_f="17125" txt_i="8207" txt_f="8218">136 (78.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17173" xml_f="17183" txt_i="8219" txt_f="8229">69 (84.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17231" xml_f="17241" txt_i="8230" txt_f="8240">17 (89.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17289" xml_f="17299" txt_i="8241" txt_f="8251">13 (81.3%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17395" xml_f="17406" txt_i="8253" txt_f="8264">132 (81.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17454" xml_f="17464" txt_i="8265" txt_f="8275">14 (63.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17512" xml_f="17522" txt_i="8276" txt_f="8286">10 (71.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17570" xml_f="17580" txt_i="8287" txt_f="8297">10 (83.3%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17635" xml_f="17653" txt_i="8298" txt_f="8316">Early mobilization</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17701" xml_f="17711" txt_i="8317" txt_f="8327">27 (87.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17759" xml_f="17770" txt_i="8328" txt_f="8339">163 (93.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17818" xml_f="17828" txt_i="8340" txt_f="8350">78 (95.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17876" xml_f="17886" txt_i="8351" txt_f="8361">17 (89.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17934" xml_f="17942" txt_i="8362" txt_f="8370">12 (75%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17990" xml_f="18001" txt_i="8371" txt_f="8382">132 (96.4%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18097" xml_f="18107" txt_i="8384" txt_f="8394">21 (95.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18155" xml_f="18165" txt_i="8395" txt_f="8405">13 (92.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18213" xml_f="18222" txt_i="8406" txt_f="8415">12 (100%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18277" xml_f="18292" txt_i="8416" txt_f="8431">GCS full length</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18340" xml_f="18348" txt_i="8432" txt_f="8440">1 (3.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18396" xml_f="18406" txt_i="8441" txt_f="8451">22 (12.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18454" xml_f="18463" txt_i="8452" txt_f="8461">11(13.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18511" xml_f="18520" txt_i="8462" txt_f="8471">2 (10.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18568" xml_f="18576" txt_i="8472" txt_f="8480">1 (6.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18624" xml_f="18634" txt_i="8481" txt_f="8491">14 (10.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18682" xml_f="18692" txt_i="8492" txt_f="8502">21 (12.9%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18788" xml_f="18795" txt_i="8504" txt_f="8511">7 (50%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18843" xml_f="18852" txt_i="8512" txt_f="8521">4 (33.3%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18907" xml_f="18921" txt_i="8522" txt_f="8536">GCS below knee</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18969" xml_f="18977" txt_i="8537" txt_f="8545">1 (3.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19025" xml_f="19034" txt_i="8546" txt_f="8555">14 (8.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19082" xml_f="19090" txt_i="8556" txt_f="8564">7 (8.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19138" xml_f="19147" txt_i="8565" txt_f="8574">4 (21.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19195" xml_f="19204" txt_i="8575" txt_f="8584">2 (12.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19252" xml_f="19261" txt_i="8585" txt_f="8594">10 (7.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19309" xml_f="19318" txt_i="8595" txt_f="8604">13 (8.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19366" xml_f="19375" txt_i="8605" txt_f="8614">7 (31.8%)</offsets></td><td align="center" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19471" xml_f="19478" txt_i="8616" txt_f="8623">3 (25%)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19533" xml_f="19536" txt_i="8624" txt_f="8627">IPC</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19584" xml_f="19592" txt_i="8628" txt_f="8636">1 (3.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19640" xml_f="19649" txt_i="8637" txt_f="8646">12 (6.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19697" xml_f="19705" txt_i="8647" txt_f="8655">5 (6.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19753" xml_f="19762" txt_i="8656" txt_f="8665">2 (10.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19810" xml_f="19816" txt_i="8666" txt_f="8672">0 (0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19864" xml_f="19873" txt_i="8673" txt_f="8682">10 (7.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19921" xml_f="19930" txt_i="8683" txt_f="8692">12 (7.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="19978" xml_f="19987" txt_i="8693" txt_f="8702">4 (18.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="20035" xml_f="20044" txt_i="8703" txt_f="8712">3 (21.4%)</offsets></td><td align="center" rowspan="1" colspan="1"></td></tr></tbody></table></table-wrap><p><offsets xml_i="20134" xml_f="20601" txt_i="8714" txt_f="9181">The majority of centers used prophylactic methods routinely in all immobile stroke patients (105/176, 59.7%). Others used prophylaxis (this presumably mainly referred to anticoagulants) routinely only in those in whom intracranial hemorrhage had been excluded (62/176, 35%) or only in those thought to be at particularly high risk of VTE development (13/176, 7.3%). In 8/176 (4.5%) centers the decision on the choice of prophylactic method was based on other factors.</offsets></p><p><offsets xml_i="20608" xml_f="20903" txt_i="9182" txt_f="9477">The majority of centers (115/176, 65%) were interested in joining a randomized trial evaluating any of the prevention methods of VTE in stroke patients. Six centers did not answer this question. Large centers were more interested in taking part in such a study than smaller ones (70.7% vs. 45%, </offsets><italic><offsets xml_i="20911" xml_f="20912" txt_i="9477" txt_f="9478">p</offsets></italic><offsets xml_i="20921" xml_f="21354" txt_i="9478" txt_f="9911"> = 0.039). Most of the surveyed centers were interested in joining a randomized trial evaluating LMWH (111/170, 63%). The centers willing to participate in the randomized trial were less interested (24/170, 13.6%) in joining a trial evaluating the safety and efficacy of dextrans. A detailed presentation of the preferred methods of prevention among centers that would be interested in evaluating such methods in a randomized study (</offsets><italic><offsets xml_i="21362" xml_f="21363" txt_i="9911" txt_f="9912">n</offsets></italic><offsets xml_i="21372" xml_f="21395" txt_i="9912" txt_f="9935"> = 115) is provided in </offsets><xref ref-type="fig" rid="F0002"><offsets xml_i="21428" xml_f="21436" txt_i="9935" txt_f="9943">Figure 2</offsets></xref><offsets xml_i="21443" xml_f="21444" txt_i="9943" txt_f="9944">.</offsets></p><fig id="F0002" position="float"><label><offsets xml_i="21488" xml_f="21496" txt_i="9945" txt_f="9953">Figure 2</offsets></label><caption><p><offsets xml_i="21516" xml_f="21654" txt_i="9953" txt_f="10091">Preferred methods of VTE prevention to be evaluated among centers willing to participate in the randomized study evaluating such methods (</offsets><italic><offsets xml_i="21662" xml_f="21663" txt_i="10091" txt_f="10092">n</offsets></italic><offsets xml_i="21672" xml_f="21673" txt_i="10092" txt_f="10093">/</offsets><italic><offsets xml_i="21681" xml_f="21682" txt_i="10093" txt_f="10094">N</offsets></italic><offsets xml_i="21691" xml_f="21708" txt_i="10094" txt_f="10111"> = 115/170, 65%).</offsets></p></caption><graphic xlink:href="AMS-10-23014-g002"></graphic></fig><p><offsets xml_i="21781" xml_f="22026" txt_i="10112" txt_f="10357">We performed a comparative analysis of centers with a stroke unit (132/176) and those without (38/176). The only method practiced by centers with a stroke unit that was statistically more frequently used was early mobilization (94.9% vs. 84.6%, </offsets><italic><offsets xml_i="22034" xml_f="22035" txt_i="10357" txt_f="10358">p</offsets></italic><offsets xml_i="22044" xml_f="22134" txt_i="10358" txt_f="10448"> = 0.04). Dextrans were less frequently used in centers with a stroke unit (6.6% vs. 13%, </offsets><italic><offsets xml_i="22142" xml_f="22143" txt_i="10448" txt_f="10449">p</offsets></italic><offsets xml_i="22152" xml_f="22335" txt_i="10449" txt_f="10632"> = 0.05). The centers with a stroke unit were also more willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients (95/132 vs. 20/38; </offsets><italic><offsets xml_i="22343" xml_f="22344" txt_i="10632" txt_f="10633">p</offsets></italic><offsets xml_i="22353" xml_f="22476" txt_i="10633" txt_f="10756"> = 0.031), but there were no statistical differences regarding the methods of prevention that centers would like to assess.</offsets></p><p><offsets xml_i="22483" xml_f="22755" txt_i="10757" txt_f="11026">Additionally we compared the centers admitting &lt; 200 patients/year with those admitting ≥ 200 patients/year. New oral anticoagulants were more frequently (214/156 vs. 5/20) used in centers admitting less than 200 patients per year, which was statistically significant (</offsets><italic><offsets xml_i="22763" xml_f="22764" txt_i="11026" txt_f="11027">p</offsets></italic><offsets xml_i="22773" xml_f="23007" txt_i="11027" txt_f="11258"> = 0.046). There were no other statistical differences between centers admitting ≥ 200 and &lt; 200 patients per year in terms of using other methods of prophylaxis or being willing to participate in a trial evaluating those methods (</offsets><italic><offsets xml_i="23015" xml_f="23016" txt_i="11258" txt_f="11259">p</offsets></italic><offsets xml_i="23025" xml_f="23190" txt_i="11259" txt_f="11421"> &gt; 0.05). Centers admitting ≥ 200 per year were more interested in joining randomized trials evaluating any of the methods used in VTE prophylaxis (70.67 vs. 45; </offsets><italic><offsets xml_i="23198" xml_f="23199" txt_i="11421" txt_f="11422">p</offsets></italic><offsets xml_i="23208" xml_f="23292" txt_i="11422" txt_f="11506"> = 0.039), but no statistical differences in terms of particular methods were found.</offsets></p></sec><sec sec-type="discussion" id="S0004"><title><offsets xml_i="23347" xml_f="23357" txt_i="11508" txt_f="11518">Discussion</offsets></title><p><offsets xml_i="23368" xml_f="24033" txt_i="11519" txt_f="12184">In this survey representing practice patterns in 176 Polish neurological wards and/or stroke units we found that all centers used several methods of VTE prophylaxis in stroke patients. Low molecular weight heparin was the dominant method for prophylaxis, although there are no randomized trials comparing the use of LMWH vs. placebo to prevent VTE in stroke patients. Both American and European guidelines suggest the use of heparins (UFH and LMWH) in VTE prevention in stroke patients, but suggest their use mostly in those considered to be at high risk of VTE and low risk of bleeding – interpretation of this recommendation may be problematic and controversial [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="24069" xml_f="24070" txt_i="12184" txt_f="12185">7</offsets></xref><offsets xml_i="24077" xml_f="24079" txt_i="12185" txt_f="12187">, </offsets><xref rid="CIT0009" ref-type="bibr"><offsets xml_i="24115" xml_f="24116" txt_i="12187" txt_f="12188">9</offsets></xref><offsets xml_i="24123" xml_f="24124" txt_i="12188" txt_f="12189">–</offsets><xref rid="CIT0011" ref-type="bibr"><offsets xml_i="24160" xml_f="24162" txt_i="12189" txt_f="12191">11</offsets></xref><offsets xml_i="24169" xml_f="24171" txt_i="12191" txt_f="12193">, </offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="24207" xml_f="24209" txt_i="12193" txt_f="12195">13</offsets></xref><offsets xml_i="24216" xml_f="24387" txt_i="12195" txt_f="12366">]. The grade of the recommendation varies, which may result from the different interpretation of the evidence and the differences in historical choices in those countries.</offsets></p><p><offsets xml_i="24394" xml_f="24539" txt_i="12367" txt_f="12512">Early mobilization was practiced in 92.6% of centers. Although there is an ongoing debate about the definition and effectiveness of this method [</offsets><xref rid="CIT0015" ref-type="bibr"><offsets xml_i="24575" xml_f="24577" txt_i="12512" txt_f="12514">15</offsets></xref><offsets xml_i="24584" xml_f="24655" txt_i="12514" txt_f="12585">], it is recommended by European Stroke Organization (ESO) guidelines [</offsets><xref rid="CIT0012" ref-type="bibr"><offsets xml_i="24691" xml_f="24693" txt_i="12585" txt_f="12587">12</offsets></xref><offsets xml_i="24700" xml_f="24800" txt_i="12587" txt_f="12687">], as well as by the newest Polish guidelines of stroke treatment and prevention published in 2012 [</offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="24836" xml_f="24838" txt_i="12687" txt_f="12689">13</offsets></xref><offsets xml_i="24845" xml_f="24918" txt_i="12689" txt_f="12762">]. The latest American guidelines do not mention the use of this method [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="24954" xml_f="24955" txt_i="12762" txt_f="12763">7</offsets></xref><offsets xml_i="24962" xml_f="25300" txt_i="12763" txt_f="13101">]. There are no trials that have evaluated the effectiveness of this method in VTE prevention in stroke patients. Moreover, the ongoing AVERT trial (A Very Early Rehabilitation Trial for Stroke) will also not answer whether this method is effective in VTE prevention as it is trying to test its effect on functional outcomes but not VTE [</offsets><xref rid="CIT0016" ref-type="bibr"><offsets xml_i="25336" xml_f="25338" txt_i="13101" txt_f="13103">16</offsets></xref><offsets xml_i="25345" xml_f="25347" txt_i="13103" txt_f="13105">].</offsets></p><p><offsets xml_i="25354" xml_f="25564" txt_i="13106" txt_f="13316">In the majority of the Polish centers (72.7% of centers) good hydration is a part of VTE prevention. Although the effectiveness of this method in stroke patients is based only on one small observational study [</offsets><xref rid="CIT0017" ref-type="bibr"><offsets xml_i="25600" xml_f="25602" txt_i="13316" txt_f="13318">17</offsets></xref><offsets xml_i="25609" xml_f="25693" txt_i="13318" txt_f="13402">], both European and Polish guidelines recommend good hydration of stroke patients [</offsets><xref rid="CIT0012" ref-type="bibr"><offsets xml_i="25729" xml_f="25731" txt_i="13402" txt_f="13404">12</offsets></xref><offsets xml_i="25738" xml_f="25740" txt_i="13404" txt_f="13406">, </offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="25776" xml_f="25778" txt_i="13406" txt_f="13408">13</offsets></xref><offsets xml_i="25785" xml_f="25794" txt_i="13408" txt_f="13417">]. Kelly </offsets><italic><offsets xml_i="25802" xml_f="25807" txt_i="13417" txt_f="13422">et al</offsets></italic><offsets xml_i="25816" xml_f="25980" txt_i="13422" txt_f="13586">. established that a marker of dehydration was associated with more frequent DVT, but the study did not show that improving hydration reduces the incidence of VTE [</offsets><xref rid="CIT0017" ref-type="bibr"><offsets xml_i="26016" xml_f="26018" txt_i="13586" txt_f="13588">17</offsets></xref><offsets xml_i="26025" xml_f="26146" txt_i="13588" txt_f="13709">]. The Cochrane systematic review of hemodilution did show a possible effect on DVT rate but this was indirect evidence [</offsets><xref rid="CIT0018" ref-type="bibr"><offsets xml_i="26182" xml_f="26184" txt_i="13709" txt_f="13711">18</offsets></xref><offsets xml_i="26191" xml_f="26193" txt_i="13711" txt_f="13713">].</offsets></p><p><offsets xml_i="26200" xml_f="26432" txt_i="13714" txt_f="13946">The GCS were reported to be less frequently used by our respondents. Two large clinical trials aimed to determine whether GCS effectively reduce the risk of DVT in stroke patients. CLOTS 1 (Clots in Legs Or sTockings after Stroke) [</offsets><xref rid="CIT0005" ref-type="bibr"><offsets xml_i="26468" xml_f="26469" txt_i="13946" txt_f="13947">5</offsets></xref><offsets xml_i="26476" xml_f="26542" txt_i="13947" txt_f="14013">] was designed to evaluate the effectiveness of thigh-length GCS (</offsets><italic><offsets xml_i="26550" xml_f="26551" txt_i="14013" txt_f="14014">n</offsets></italic><offsets xml_i="26560" xml_f="26587" txt_i="14014" txt_f="14041"> = 1256) vs. routine care (</offsets><italic><offsets xml_i="26595" xml_f="26596" txt_i="14041" txt_f="14042">n</offsets></italic><offsets xml_i="26605" xml_f="27341" txt_i="14042" txt_f="14778"> = 1262). Proximal DVT was evaluated on compression duplex ultrasound examination at 7–10 days and 25–30 days after stroke. It was the primary end point and was found in 10.0% and 10.5% of patients, respectively, which resulted in a non-significant absolute reduction in risk of 0.5% (95% CI – 1.9% to 2.9%). Moreover, stockings significantly increased the risk of skin breaks, ulcers, blisters, and skin necrosis (64 (5%) vs. 16 (1%); odds ratio 4.18, 95% CI: 2.40–7.27). The CLOTS trial 2 compared the effectiveness of thigh-length stockings with that of below-knee stockings for preventing proximal DVT in 3114 immobile, hospitalized patients with stroke. The DVT occurred more often in patients who received thigh-length stockings (</offsets><italic><offsets xml_i="27349" xml_f="27350" txt_i="14778" txt_f="14779">p</offsets></italic><offsets xml_i="27359" xml_f="27370" txt_i="14779" txt_f="14790"> = 0.008) [</offsets><xref rid="CIT0019" ref-type="bibr"><offsets xml_i="27406" xml_f="27408" txt_i="14790" txt_f="14792">19</offsets></xref><offsets xml_i="27415" xml_f="27713" txt_i="14792" txt_f="15090">]. Despite the results of CLOTS 1 and CLOTS 2 trials, this method of prophylaxis is still used in approximately 20% of Polish centers (both full length and below knee stockings). The newest version of the Polish guidelines do not recommend the routine use of GCS in post-stroke patients (Grade 2) [</offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="27749" xml_f="27751" txt_i="15090" txt_f="15092">13</offsets></xref><offsets xml_i="27758" xml_f="28028" txt_i="15092" txt_f="15362">]. National Institute of Health and Clinical Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), American College of Physicians (ACP) and American College of Chest Physicians (ACCP) guidelines recommend that GCS should not be used in stroke patients [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="28064" xml_f="28065" txt_i="15362" txt_f="15363">7</offsets></xref><offsets xml_i="28072" xml_f="28074" txt_i="15363" txt_f="15365">, </offsets><xref rid="CIT0009" ref-type="bibr"><offsets xml_i="28110" xml_f="28111" txt_i="15365" txt_f="15366">9</offsets></xref><offsets xml_i="28118" xml_f="28119" txt_i="15366" txt_f="15367">–</offsets><xref rid="CIT0011" ref-type="bibr"><offsets xml_i="28155" xml_f="28157" txt_i="15367" txt_f="15369">11</offsets></xref><offsets xml_i="28164" xml_f="28166" txt_i="15369" txt_f="15371">].</offsets></p><p><offsets xml_i="28173" xml_f="28261" txt_i="15372" txt_f="15460">Although GCS have been proven not to be effective in DVT prevention in stroke patients [</offsets><xref rid="CIT0005" ref-type="bibr"><offsets xml_i="28297" xml_f="28298" txt_i="15460" txt_f="15461">5</offsets></xref><offsets xml_i="28305" xml_f="28780" txt_i="15461" txt_f="15936">], 30.7% of all the surveyed centers declared willingness to participate in the study if it was carried out. There were no statistical differences between large and small or stroke unit and no stroke unit centers. It is worth noting that before the publication of CLOTS 1 trial results, the use of compression stockings was a widely recommended method of VTE prophylaxis. There is also a “tradition” or a habit of their use based on their effectiveness in surgical patients [</offsets><xref rid="CIT0020" ref-type="bibr"><offsets xml_i="28816" xml_f="28818" txt_i="15936" txt_f="15938">20</offsets></xref><offsets xml_i="28825" xml_f="29012" txt_i="15938" txt_f="16125">], which was probably extrapolated to patients with stroke. Nevertheless, in the United Kingdom publication of the results of the CLOTS trials had a dramatic impact on clinical practice [</offsets><xref rid="CIT0021" ref-type="bibr"><offsets xml_i="29048" xml_f="29050" txt_i="16125" txt_f="16127">21</offsets></xref><offsets xml_i="29057" xml_f="29059" txt_i="16127" txt_f="16129">].</offsets></p><p><offsets xml_i="29066" xml_f="29201" txt_i="16130" txt_f="16265">Although there is insufficient evidence to support the routine use of pneumatic compression devices to prevent VTE in stroke patients [</offsets><xref rid="CIT0008" ref-type="bibr"><offsets xml_i="29237" xml_f="29238" txt_i="16265" txt_f="16266">8</offsets></xref><offsets xml_i="29245" xml_f="29567" txt_i="16266" txt_f="16588">], this method is still practiced in some Polish neurological wards and/or stroke units (6.8%). This method has never been commonly practiced by Polish neurologists. The results of the large randomized trial CLOTS 3, which compares the effectiveness of IPC vs. None in 2876 stroke patients, will be available in May 2013 [</offsets><xref rid="CIT0022" ref-type="bibr"><offsets xml_i="29603" xml_f="29605" txt_i="16588" txt_f="16590">22</offsets></xref><offsets xml_i="29612" xml_f="29706" txt_i="16590" txt_f="16684">]. The IPC is recommended by both European and American guidelines (Grade 2c recommendation) [</offsets><xref rid="CIT0007" ref-type="bibr"><offsets xml_i="29742" xml_f="29743" txt_i="16684" txt_f="16685">7</offsets></xref><offsets xml_i="29750" xml_f="29752" txt_i="16685" txt_f="16687">, </offsets><xref rid="CIT0012" ref-type="bibr"><offsets xml_i="29788" xml_f="29790" txt_i="16687" txt_f="16689">12</offsets></xref><offsets xml_i="29797" xml_f="29865" txt_i="16689" txt_f="16757">]. Polish guidelines do not mention this method of VTE prophylaxis [</offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="29901" xml_f="29903" txt_i="16757" txt_f="16759">13</offsets></xref><offsets xml_i="29910" xml_f="29912" txt_i="16759" txt_f="16761">].</offsets></p><p><offsets xml_i="29919" xml_f="30202" txt_i="16762" txt_f="17045">As all the centers that claimed to mobilize early and use GCS or IPC were also using LMWH, and only one center claiming to use hydration did not use LMWH, this may suggest that centers that are most interested in VTE prophylaxis use a variety of physical and pharmacological methods.</offsets></p><p><offsets xml_i="30209" xml_f="30451" txt_i="17046" txt_f="17288">All the respondents (100%) considered that it would be useful to publish guidelines for VTE prevention in post-stroke patients in Polish (this would facilitate access for people who do not know the English language). The existing guidelines [</offsets><xref rid="CIT0013" ref-type="bibr"><offsets xml_i="30487" xml_f="30489" txt_i="17288" txt_f="17290">13</offsets></xref><offsets xml_i="30496" xml_f="30807" txt_i="17290" txt_f="17601">] do not address all the questions posed by Polish neurologists: they do not precisely describe the criteria of VTE prevention implementation, the time of onset and the duration of the use of those methods. The ESO guidelines for VTE prophylaxis, which are currently being developed, may answer these questions.</offsets></p><p><offsets xml_i="30814" xml_f="31096" txt_i="17602" txt_f="17884">The fact that centers with a stroke unit less frequently used dextrans in VTE prophylaxis (no data for the effectiveness of this method), and the more frequent early mobilization may suggest that those centers are more familiar with current literature and guidelines of stroke care.</offsets></p><p><offsets xml_i="31103" xml_f="31608" txt_i="17885" txt_f="18390">Due to the variation of methods used in VTE prophylaxis, it might be reasonable to publish detailed national guidelines for VTE prophylaxis in stroke patients. Such guidelines may help standardize the prophylaxis in stroke patients. They should of course be based on the results of systematic reviews and large clinical trials. We used evidence from two randomized trials to conduct this survey, suggesting that closed-ended formats yield more complete and valid demographic data than open-ended formats [</offsets><xref rid="CIT0023" ref-type="bibr"><offsets xml_i="31644" xml_f="31646" txt_i="18390" txt_f="18392">23</offsets></xref><offsets xml_i="31653" xml_f="31736" txt_i="18392" txt_f="18475">], and that appending second questionnaires to reminders maximizes response rates [</offsets><xref rid="CIT0024" ref-type="bibr"><offsets xml_i="31772" xml_f="31774" txt_i="18475" txt_f="18477">24</offsets></xref><offsets xml_i="31781" xml_f="31902" txt_i="18477" txt_f="18598">]. Our response rate was acceptably high and our findings are generalizable to neurological/stroke centers across Poland.</offsets></p><p><offsets xml_i="31909" xml_f="32132" txt_i="18599" txt_f="18822">The response rate was acceptable (80.7%), although not all centers responded to the questionnaire. We did not elicit information on the practice of combination prophylaxis with pharmacologic and nonpharmacologic approaches.</offsets></p><p></p><p><offsets xml_i="32146" xml_f="32406" txt_i="18824" txt_f="19084">Despite the limitations, the results of this survey represent the frequency of VTE prevention methods practiced by Polish neurologists and entirely justify the development of evidence-based guidelines or translation into Polish and adaptation of European ones.</offsets></p><p><offsets xml_i="32413" xml_f="32685" txt_i="19085" txt_f="19357">In conclusion, our survey identified LMWH as the most common method of VTE prophylaxis for stroke patients practiced by Polish neurologists. The variation of methods used in VTE prophylaxis justifies the need for detailed guidelines for VTE prophylaxis in stroke patients.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geerts</surname><given-names>WH</given-names></name><name><surname>Bergqvist</surname><given-names>D</given-names></name><name><surname>Pineo</surname><given-names>GF</given-names></name><etal></etal></person-group><article-title>American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)</article-title><source>Chest</source><year>2008</year><volume>133</volume><fpage>381S</fpage><lpage>453S</lpage><pub-id pub-id-type="pmid">18574271</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Sandercock</surname><given-names>P</given-names></name><name><surname>Reid</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>CLOTS Trials Collaboration. Can clinical features distinguish between immobile patients with stroke at high and low risk of deep vein thrombosis? Statistical modelling based on the CLOTS trials cohorts</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>82</volume><fpage>1067</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">21357988</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>André</surname><given-names>C</given-names></name><name><surname>de Freitas</surname><given-names>GR</given-names></name><name><surname>Fukujima</surname><given-names>MM</given-names></name></person-group><article-title>Prevention of deep venous thrombosis and pulmonary embolism following stroke: a systematic review of published articles</article-title><source>Eur J Neurol</source><year>2007</year><volume>14</volume><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17222109</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oczkowski</surname><given-names>WJ</given-names></name><name><surname>Ginsberg</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>A</given-names></name><name><surname>Panju</surname><given-names>A</given-names></name></person-group><article-title>Venous thromboembolism in patients undergoing rehabilitation for stroke</article-title><source>Arch Phys Med Rehabil</source><year>1992</year><volume>73</volume><fpage>712</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">1642519</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><collab>The CLOTS Trials Collaboration</collab><article-title>Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1958</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">19477503</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bembenek</surname><given-names>JP</given-names></name><name><surname>Czlonkowska</surname><given-names>A</given-names></name><name><surname>Karlinski</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name></person-group><article-title>Early stroke-related DVT is more than just DVT diagnosed early after stroke onset</article-title><source>Thromb Res</source><year>2011</year><volume>128</volume><fpage>587</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">21872300</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lansberg</surname><given-names>MG</given-names></name><name><surname>O'Donnell</surname><given-names>MJ</given-names></name><name><surname>Khatri</surname><given-names>P</given-names></name><collab>American College of Chest Physicians</collab></person-group><article-title>Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title><source>Chest</source><year>2012</year><volume>141</volume><issue>Suppl 2</issue><fpage>e601S</fpage><lpage>36S</lpage><pub-id pub-id-type="pmid">22315273</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naccarato</surname><given-names>M</given-names></name><name><surname>Chiodo Grandi</surname><given-names>F</given-names></name><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Sandercock</surname><given-names>PA</given-names></name></person-group><article-title>Physical methods for preventing deep vein thrombosis in stroke</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>8</volume><fpage>CD001922</fpage><pub-id pub-id-type="pmid">20687069</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="webpage"><collab>National Institute for Health and Clinical Excellence</collab><article-title>Venous thromboembolism: reducing the risk – full guideline</article-title><year>2012</year><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://guidance.nice.org.uk/CG92">http://guidance.nice.org.uk/CG92</ext-link></comment></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="webpage"><collab>SIGN Guideline 118</collab><article-title>Management of patients with stroke: rehabilitation, prevention and management of complications, and discharge planning</article-title><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.sign.ac.uk/pdf/sign118.pdf">http://www.sign.ac.uk/pdf/sign118.pdf</ext-link></comment></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qaseem</surname><given-names>A</given-names></name><name><surname>Chou</surname><given-names>R</given-names></name><name><surname>Humphrey</surname><given-names>LL</given-names></name><etal></etal></person-group><article-title>Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians</article-title><source>Ann Intern Med</source><year>2011</year><volume>155</volume><fpage>625</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">22041951</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><collab>The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee</collab><article-title>Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008</article-title><source>Cerebrovasc Dis</source><year>2008</year><volume>25</volume><fpage>457</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">18477843</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><collab>Postępowanie w udarze mózgu</collab><article-title>Wytyczne Grupy Ekspertów Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego [Polish]</article-title><source>Neurol Neurochir Pol</source><year>2012</year><volume>46</volume><issue>Suppl.1</issue><fpage>S1</fpage><lpage>122</lpage></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutinho</surname><given-names>JM</given-names></name><name><surname>Seelig</surname><given-names>R</given-names></name><name><surname>Bousser</surname><given-names>MG</given-names></name><etal></etal></person-group><article-title>Treatment variations in cerebral venous thrombosis: an international survey</article-title><source>Cerebrovasc Dis</source><year>2011</year><volume>32</volume><fpage>298</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">21912111</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundseth</surname><given-names>A</given-names></name><name><surname>Thommessen</surname><given-names>B</given-names></name><name><surname>Rønning</surname><given-names>OM</given-names></name></person-group><article-title>Outcome after mobilization within 24 hours of acute stroke: a randomized controlled trial</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>2389</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">22700533</pub-id></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorbello</surname><given-names>D</given-names></name><name><surname>Dewey</surname><given-names>HM</given-names></name><name><surname>Churilov</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Very early mobilisation and complications in the first 3 months after stroke: further results from phase II of A Very Early Rehabilitation Trial (AVERT)</article-title><source>Cerebrovasc Dis</source><year>2009</year><volume>28</volume><fpage>378</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19641313</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>BJ</given-names></name><name><surname>Lewis</surname><given-names>RR</given-names></name><etal></etal></person-group><article-title>Dehydration and venous thromboembolism after acute stroke</article-title><source>QJM</source><year>2004</year><volume>97</volume><fpage>293</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15100423</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asplund</surname><given-names>K</given-names></name></person-group><article-title>Haemodilution for acute ischaemic stroke</article-title><source>Cochrane Database Syst Rev</source><year>2002</year><volume>4</volume><fpage>CD000103</fpage><pub-id pub-id-type="pmid">12519536</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><collab>CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration</collab><article-title>Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial</article-title><source>Ann Intern Med</source><year>2010</year><volume>153</volume><fpage>553</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">20855784</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>PS</given-names></name><name><surname>Lensing</surname><given-names>AWA</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name></person-group><article-title>Graduated compression stockings in the prevention of postoperative venous thromboembolism: a meta analysis</article-title><source>Arch Intern Med</source><year>1994</year><volume>154</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8267491</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sett</surname><given-names>A</given-names></name><name><surname>Mistri</surname><given-names>A</given-names></name></person-group><article-title>A dramatic impact of the CLOTS Studies on clinical practice in the UK</article-title><source>Int J Stroke</source><year>2011</year><volume>6</volume><fpage>15</fpage></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>M</given-names></name><name><surname>Sandercock</surname><given-names>P</given-names></name><name><surname>Reid</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>CLOTS Trials Collaboration. Does intermittent pneumatic compression reduce the risk of post stroke deep vein thrombosis? The CLOTS 3 trial: study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2012</year><volume>13</volume><fpage>26</fpage><pub-id pub-id-type="pmid">22400901</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Charles</surname><given-names>C</given-names></name></person-group><article-title>Comparison of open versus closed questionnaire formats in obtaining demographic information from Canadian general internists</article-title><source>J Clin Epidemiol</source><year>1999</year><volume>52</volume><fpage>997</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">10513763</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asch</surname><given-names>DA</given-names></name><name><surname>Jedrziewski</surname><given-names>MK</given-names></name><name><surname>Christakis</surname><given-names>NA</given-names></name></person-group><article-title>Response rates to mail surveys published in medical journals</article-title><source>J Clin Epidemiol</source><year>1997</year><volume>50</volume><fpage>1129</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9368521</pub-id></element-citation></ref></ref-list><sec id="S0005"><label>Supplement 1</label><title>Questionnaire</title><p>Filling in this questionnaire will take you about 2 minutes. After filling in the questionnaire please send it back to the e-mail address <email xlink:href="jbembenek@yahoo.com">jbembenek@yahoo.com</email> or put it in the included stamped addressed envelope and send it to the following address:</p><p>2<sup>nd</sup> Department of Neurology</p><p>Institute of Psychiatry and Neurology</p><p>Ul. Sobieskiego 9</p><p>02-957 Warsaw</p><p>Please write your name, name of hospital, and voivodship. If you put your e-mail address we will send you the results of the survey:</p><p>.............................................................................................</p><p>.............................................................................................</p><p>.............................................................................................</p><p>.............................................................................................</p><p>.............................................................................................</p><p>            Yes  No</p><p>1) Do you have a stroke unit in your hospital?   □  □</p><p>2) Which of the following methods do you use, either routinely or in selected patients, in stroke patients? You may put more than one tick.</p><p>  a) UFH – unfractionated heparin   □</p><p>  b) LMWH – low-molecular-weight heparin   □</p><p>  c) Oral anticoagulants</p><p>  d) New oral anticoagulants   □</p><p>  e) Dextrans     □</p><p>  f) Hydration     □</p><p>  g) Early mobilization     □</p><p>  h) Graduated compression stockings</p><p>   1) Full length     □</p><p>   2) Below knee     □</p><p>  i) Intermittent pneumatic compression devices   □</p><p>Please indicate whether you use each of these methods.</p><p> •Routinely, in all immobile stroke patients     □</p><p> •Routinely in those in whom hemorrhage has been excluded □</p><p> •Only those thought to be at particularly high risk     □</p><p> •Other option – please specify</p><p>.............................................................................................</p><p>.............................................................................................</p><p>3) Would you be interested in joining a randomized trial evaluating the efficacy of the following?</p><p>          Yes  No</p><p>  a) UFH – unfractionated heparin   □  □</p><p>  b) LMWH – low-molecular-weight heparin   □  □</p><p>  c) Oral anticoagulants    □  □</p><p>  d) Dextrans    □  □</p><p>  e) Graduated compression stockings   □  □</p><p>  f) Intermittent pneumatic compression devices   □  □</p><p>4) How many stroke patients do you admit a year? Put the approximate number, please.</p><p>.............................................................................................</p><p>.............................................................................................</p><p>5) Do you think it would be useful to develop some Polish guidelines for preventing DVT after stroke?</p><p>            Yes  No</p><p>          □  □</p><p>Thank you very much for your co-operation.</p></sec></back></article>